| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 22, 2025 4:01 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
SCHEDULE 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date Strengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025 Cambridge, Massachusetts, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral scleros
Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial enrollment following DSMB recommendation to proceed to second dose level CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer's Disease (AD), amyotrophic l
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has entered into a purchase agreement (the "Purchase Agreement") with existing institutional and accredited investors to issue and sell an aggregate of approximately $3.0 million of warrants (the "Warrants"). The Warrants were sold at a price of $0.1875 per share through a private
3 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4/A - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4/A - ProMIS Neurosciences Inc. (0001374339) (Issuer)
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)